Treatment of patients with multiple brain metastases by isolated radiosurgery:Toxicity and survival  

Treatment of patients with multiple brain metastases by isolated radiosurgery:Toxicity and

作　　者：AndréVinícius de Camargo Marcos Duarte de Mattos Murilo Kenji Kawasaki Danilo Nascimento Salviano Gomes Allisson Bruno Barcelos Borges Vinicius de Lima Vazquez Raphael L C Araujo 

机构地区：[1]Department of Radiotherapy,Barretos Cancer Hospital,São Paulo,Barretos 14784-400,Brazil [2]Department of Radiation Therapy,Hospital DF Star Rede D´Or,Brasília 70390-140,Brazil [3]Department of Surgery,Barretos Cancer Hospital,São Paulo,Barretos 14784-400,Brazil [4]Department of Surgery,Universidade Federal de São Paulo,São Paulo 04024-002,Brazil [5]IEP,Barretos Cancer Hospital,São Paulo,Barretos 14784-400,Brazil

出　　处：《World Journal of Clinical Oncology》2023年第10期400-408,共9页世界临床肿瘤学杂志（英文版）

摘　　要：BACKGROUND Radiosurgery for multiple brain metastases has been more reported recently without using whole-brain radiotherapy.Nevertheless,the sparsity of the data still claims more information about toxicity and survival and their association with both dosimetric and geometric aspects of this treatment.AIM To assess the toxicity and survival outcome of radiosurgery in patients with multiple(four or more lesions)brain metastases.METHODS In a single institution,data were collected retrospectively from patients who underwent radiosurgery to treat brain metastases from diverse primary sites.Patients with 4-21 brain metastases were treated with a single fraction with a dose of 18 Gy or 20 Gy.The clinical variables collected were relevant to toxicity,survival,treatment response,planning,and dosimetric variables.The Spearman’s rank correlation coefficients,Mann-Whitney test,Kruskal-Wallis test,and Log-RESULTS From August 2017 to February 2020,55 patients were evaluated.Headache was the most common complaint(38.2%).The median overall survival(OS)for patients with karnofsky performance status(KPS)>70 was 8.9 mo,and this was 3.6 mo for those with KPS≤70(P=0.047).Patients with treated lesions had a median progression-free survival of 7.6 mo.There were no differences in OS(19.7 vs 9.5 mo)or progression-free survival(10.6 vs 6.3 mo)based on prior irradiation.There was no correlation found between reported toxicities and planning,dosimetric,and geometric variables,implying that no additional significant toxicity risks appear to be added to the treatment of multiple(four or more)lesions.CONCLUSION No associations were found between the evaluated toxicities and the planning dosimetric parameters,and no differences in survival rates were detected based on previous treatment status.

关 键 词：RADIOSURGERY Brain metastases RADIOTHERAPY SURVIVAL TOXICITY CANCER 

分 类 号：R735.34[医药卫生—肿瘤]